Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Sep 2011
Comparative StudyActivation and entrainment mapping of hemodynamically unstable ventricular tachycardia using a percutaneous left ventricular assist device.
Our goal was to investigate the effects of percutaneous left ventricular assist device (pLVAD) support during catheter ablation of unstable ventricular tachycardia (VT). ⋯ In patients with scar-related VT undergoing catheter ablation, pLVAD support was able to safely maintain end-organ perfusion despite extended periods of hemodynamically unstable VT. Randomized studies are necessary to determine whether this enhanced ability to perform entrainment and activation mapping will translate into a higher rate of clinical success.
-
J. Am. Coll. Cardiol. · Sep 2011
Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance.
The purpose of this study was to define the incidence and characterization of cardiovascular cause of sudden death in the young. ⋯ Prevention of sudden death in the young adult should focus on evaluation for causes known to be associated with SUD (e.g., primary arrhythmia) among persons <35 years of age, with an emphasis on atherosclerotic coronary disease in those ≥ 35 years of age.
-
J. Am. Coll. Cardiol. · Sep 2011
Review Meta AnalysisEffects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis.
The aim of this systematic review was to study the benefits and risks of beta-adrenergic antagonists (beta-blockers) in patients with chronic kidney disease (CKD). ⋯ Treatment with beta-blockers improved all-cause mortality in patients with CKD and chronic systolic heart failure. There is insufficient evidence to conclude whether people with CKD who are not known to have heart failure derive benefit from beta-blockers.
-
J. Am. Coll. Cardiol. · Aug 2011
Multicenter StudyMidregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
The aim of this study was to determine the prognostic utility of midregion proadrenomedullin (MR-proADM) in all patients, cardiac and noncardiac, presenting with acute shortness of breath. ⋯ MR-proADM identifies patients with high 90-day mortality and adds prognostic value to natriuretic peptides in patients presenting with acute shortness of breath. Serial measurement of this biomarker may also prove useful for monitoring, although further studies will be required. (Biomarkers in Acute Heart Failure [BACH]; NCT00537628).